Autosomal recessive osteopetrosis

For TCIRG1 c.2236+1G>A, a canonical splice donor variant expected to produce non-functional a3 subunit of the vacuolar H+-ATPase in osteoclasts, ex vivo hematopoietic stem/progenitor cell (HSPC) gene therapy with lentiviral TCIRG1 delivery represents the most promising curative approach beyond allogeneic HSCT. TCIRG1 mutations account for >50% of autosomal recessive osteopetrosis (ARO) cases. Because osteoclasts derive from the hematopoietic lineage, correcting HSPCs with a functional TCIRG1 transgene can restore osteoclast acidification capacity. This approach avoids the graft-versus-host disease risk, donor availability constraints, and high transplant-related mortality (20-40%) associated with allogeneic HSCT in ARO.

Preclinical proof-of-concept has been demonstrated in the oc/oc mouse model (TCIRG1-null): transplantation of lentiviral-corrected HSPCs restored osteoclast function and normalized bone density. Rocket Pharmaceuticals is developing RP-L401 (formerly TGRN-001), a lentiviral HSPC gene therapy for TCIRG1-deficient ARO, which has received FDA Rare Pediatric Disease and Orphan Drug designations. The program uses a codon-optimized TCIRG1 cDNA driven by a ubiquitous promoter (PGK or EFS) in a self-inactivating lentiviral vector. Clinical trials are in early-phase development. Allogeneic HSCT remains the current standard of care but has significant limitations: matched donors are unavailable for ~30% of patients, and transplant mortality in ARO (particularly with mismatched donors) remains 20-40% due to graft failure and organ damage from the dense bone marrow environment.

Lentiviral HSPC gene therapy requires myeloablative conditioning (typically busulfan-based) to create marrow space, which carries toxicity risks especially in the dense, fibrotic marrow environment of ARO patients. Engraftment may be impaired by the osteosclerotic niche. The bone marrow space in severe ARO is progressively obliterated, and delayed treatment reduces the likelihood of successful engraftment — early intervention (ideally before 3-6 months of age) is critical. It remains uncertain whether gene-corrected osteoclasts can remodel already pathologically dense bone, or whether intervention must precede the establishment of severe skeletal disease. Long-term transgene expression from integrated lentivirus is generally durable, but insertional mutagenesis risk is non-zero. For the specific c.2236+1G>A splice variant, confirming complete loss of exon inclusion (rather than residual cryptic splicing) is important for genotype-phenotype correlation.

For TCIRG1 c.1674-1G>A, a pathogenic splice acceptor variant predicted to disrupt exon 15 splicing and abolish a3 subunit function in osteoclasts, lentiviral ex vivo gene therapy using autologous CD34+ HSPCs transduced with a functional TCIRG1 transgene offers a potentially safer alternative to allogeneic hematopoietic stem cell transplantation (HSCT). Autosomal recessive osteopetrosis (ARO) due to TCIRG1 mutations accounts for ~50% of all ARO cases and is lethal without treatment. While allogeneic HSCT is curative by replacing the osteoclast lineage, it carries significant morbidity from graft-versus-host disease, graft failure, and conditioning-related toxicity. Ex vivo lentiviral gene correction of autologous HSPCs eliminates donor-related risks while providing functional osteoclasts derived from the corrected stem cell compartment.

Preclinical studies have demonstrated that lentiviral TCIRG1 gene transfer into Tcirg1-deficient murine HSPCs rescues osteoclast function and corrects the osteopetrotic phenotype after transplantation (Moscatelli et al., Hum Gene Ther 2018; PMID:29706106). Patient-derived CD34+ cells transduced with lentiviral TCIRG1 vectors show restored osteoclast resorption activity in vitro, confirming that gene addition restores the functional deficit (Lanzi et al., Bone 2020; PMID:32169673). The splice variant c.1674-1G>A disrupts the invariant AG at the exon 15 splice acceptor, expected to cause exon skipping and loss of the a3 subunit of the vacuolar H+-ATPase, which is essential for osteoclast acid secretion and bone resorption. ClinVar classifies this as Pathogenic. The Rocket Pharmaceuticals RP-L401 program represents clinical-stage lentiviral TCIRG1 gene therapy development, with IND-enabling studies completed.

No clinical efficacy data for lentiviral TCIRG1 gene therapy are available yet. ARO patients typically present in infancy with life-threatening complications (pancytopenia, cranial nerve compression, hepatosplenomegaly), requiring urgent intervention — the manufacturing timeline for autologous gene therapy (cell collection, transduction, quality release) may be incompatible with the clinical urgency in severely affected neonates. Conditioning regimens, though potentially reduced compared to allogeneic HSCT, are still required for engraftment and carry toxicity risks in fragile infants. Insertional mutagenesis risk from lentiviral integration, while lower than with gamma-retroviral vectors, cannot be entirely excluded. Long-term durability of transgene expression from the lentiviral-transduced HSC compartment needs verification. For patients with an available matched sibling donor, allogeneic HSCT remains the established standard with good outcomes, so gene therapy may be most valuable for patients lacking suitable donors.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Autosomal recessive osteopetrosis targeting the TCIRG1 c.630G>A (p.Thr210=) variant (Pathogenic, 5 prime UTR variant, synonymous variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct loss-of-function TCIRG1 mutations in hematopoietic stem cells at the TCIRG1 locus to restore osteoclast acidification and cure autosomal recessive osteopetrosis. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: TCIRG1 NM_006019.4(TCIRG1):c.630G>A (p.Thr210=) is classified as Pathogenic (ClinVar variation ID 1458586). Molecular consequence: 5 prime UTR variant, synonymous variant. 2. Epidemiology: Incidence approximately 1 in 200,000-250,000 live births with higher prevalence in consanguineous populations; over 50% of ARO due to TCIRG1, 10-15% due to CLCN7, smaller fractions due to OSTM1, CA2 and others. 3. Standard of care: Early allogeneic hematopoietic stem cell transplantation is the only curative option for osteoclast-intrinsic forms; ACTIMMUNE (interferon gamma-1b) is FDA-approved to delay progression as adjunctive, non-curative therapy; additional care is supportive (transfusions, infection management, orthopedic 4. Pipeline: HSCT is established standard of care; interferon gamma-1b is approved pharmacologic therapy; lentiviral ex vivo TCIRG1 gene therapy is in preclinical development with murine rescue data; no registered CRISPR or other gene-editing clinical trials for ARO as of 2024; gene-editing work remains preclini 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting TCIRG1 c.630G>A (p.Thr210=) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.